[ {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4",
    "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ],
    "http://www.nanopub.org/nschema#hasAssertion" : [ {
      "@id" : "http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#assertion"
    } ],
    "http://www.nanopub.org/nschema#hasProvenance" : [ {
      "@id" : "http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#provenance"
    } ],
    "http://www.nanopub.org/nschema#hasPublicationInfo" : [ {
      "@id" : "http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#pubinfo"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#Head"
}, {
  "@graph" : [ {
    "@id" : "http://purl.obolibrary.org/obo/DOID_7148",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Disease"
    } ]
  }, {
    "@id" : "http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#association",
    "@type" : [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ {
      "@id" : "http://purl.obolibrary.org/obo/DOID_7148"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ {
      "@id" : "https://w3id.org/biolink/vocab/treats"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ {
      "@id" : "https://identifiers.org/drugbank:DB08895"
    } ],
    "http://www.w3.org/2000/01/rdf-schema#label" : [ {
      "@value" : "xeljanz xeljanz xr is a janus kinase jak inhibitor rheumatoid arthritis limitations of use 1 psoriatic arthritis limitations of use 1 ulcerative colitis limitations of use 1 rheumatoid arthritis xeljanz xeljanz xr is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate it may be used as monotherapy or in combination with methotrexate or other nonbiologic disease modifying antirheumatic drugs dmards limitations of use use of xeljanz xeljanz xr in combination with biologic dmards or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended psoriatic arthritis xeljanz xeljanz xr is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease modifying antirheumatic drugs dmards limitations of use use of xeljanz xeljanz xr in combination with biologic dmards or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended ulcerative colitis xeljanz is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis uc limitations of use use of xeljanz in combination with biological therapies for uc or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended"
    } ],
    "https://w3id.org/biolink/vocab/association_type" : [ {
      "@id" : "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation"
    } ],
    "https://w3id.org/biolink/vocab/provided_by" : [ {
      "@id" : "https://w3id.org/um/NeuroDKG"
    } ],
    "https://w3id.org/biolink/vocab/relation" : [ {
      "@id" : "https://schema.org/TreatmentIndication"
    } ]
  }, {
    "@id" : "https://identifiers.org/drugbank:DB08895",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Drug"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#assertion"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#assertion",
    "http://www.w3.org/ns/prov#wasAttributedTo" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#provenance"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4",
    "http://purl.org/dc/terms/created" : [ {
      "@type" : "http://www.w3.org/2001/XMLSchema#dateTime",
      "@value" : "2021-07-03T14:28:19.986+02:00"
    } ],
    "http://purl.org/dc/terms/creator" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate" : [ {
      "@id" : "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate" : [ {
      "@id" : "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ {
      "@id" : "http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs"
    } ]
  }, {
    "@id" : "http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#sig",
    "http://purl.org/nanopub/x/hasAlgorithm" : [ {
      "@value" : "RSA"
    } ],
    "http://purl.org/nanopub/x/hasPublicKey" : [ {
      "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
    } ],
    "http://purl.org/nanopub/x/hasSignature" : [ {
      "@value" : "JMe/DXRQeGZNv9fu1EXp2k0u5UBrXUb4STGw8AkfBSl7u8VeiPFv+g18jeriV0ELaFb6rfaTCoqgPk/QIaxt466NVpmuG1j4U+EuXf5X0JunaHZrMHgWdR2256HzyAtQBtDMayuapCht9EzeEmwDwatEv6SnfoZeOzc0sGVXgGM="
    } ],
    "http://purl.org/nanopub/x/hasSignatureTarget" : [ {
      "@id" : "http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#pubinfo"
} ]